Biosele - Company finances
|
EUR
|
2021
From: 2021-07-05
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|
|
Financial data
|
|||||
| Sales revenue | 2,358 | 3,936 | 7,494 | 13,784 | 9,141 |
| Profit before tax | - | - | - | - | - |
| Net profit | -3,708 | -2,232 | 2,718 | 2,658 | 16 |
| Equity | -1,208 | -3,440 | -722 | 1,537 | 1,554 |
| Liabilities | 3,431 | 4,007 | 2,172 | 3,387 | 2,898 |
| Non-current assets | 0 | 0 | 0 | 0 | 0 |
| Current assets | 2,223 | 149 | 1,203 | 3,607 | 4,452 |
| Total assets | 2,223 | 149 | 1,203 | 3,607 | 4,452 |
|
Taxes paid
|
|||||
| STI taxes | - | - | 89 | 1,420 | 1,056 |
|
Financial indicators
|
|||||
| Revenue change y/y | - | +66.9% | +90.4% | +83.9% | -33.7% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -166.8% | -1498.0% | 225.9% | 73.7% | 0.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | 172.9% | 1.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -157.3% | -56.7% | 36.3% | 19.3% | 0.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | 2.2 | 1.9 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 2,358 | 3,936 | 7,494 | 13,784 | 9,141 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biosele - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-07-23 | 2026-08-09 | 0.58 |
| 2026-06-16 | 2026-06-25 | 196.89 |
| 2022-01-18 | 2022-01-27 | 136.55 |
| 2021-11-17 | 2021-12-14 | 0.08 |
| 2021-11-16 | 2021-11-16 | 71.61 |
| 2021-11-08 | 2021-11-15 | 0.08 |
| 2021-09-16 | 2021-09-16 | 136.55 |
Biosele - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-09-30 | 2025-10-26 | 0.04 |
| 2025-09-28 | 2025-09-29 | 25.01 |
| 2025-08-01 | 2025-08-25 | 0.01 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biosele, UAB (code 305815595) is a Private Limited Liability Company operating in other non-specialised retail sale. In 2025, the company generated revenue of €9.1K and net profit of €16, resulting in a profit margin of 0.2%. Revenue decreased by 33.7% year on year, although the two-year change remains positive at 22.0%, indicating that 2025 sales were still above the 2023 level. The revenue path was €7.5K in 2023, €13.8K in 2024 and €9.1K in 2025, while net profit was €2.7K in both 2023 and 2024 before falling sharply in 2025. At the end of 2025, total assets stood at €4.5K, equity at €1.6K and liabilities at €2.9K. The equity ratio was 34.9%, debt-to-equity 1.86 and asset turnover 2.05x. Return on equity was 1.0% and return on assets 0.4%. Revenue per employee was €9.1K, with profit per employee of €16.